ID   GSK3B_HUMAN             Reviewed;         420 AA.
AC   P49841; Q9BWH3; Q9UL47;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   02-MAY-2002, sequence version 2.
DT   02-NOV-2010, entry version 139.
DE   RecName: Full=Glycogen synthase kinase-3 beta;
DE            Short=GSK-3 beta;
DE            EC=2.7.11.26;
GN   Name=GSK3B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF SER-9.
RX   MEDLINE=95071278; PubMed=7980435;
RA   Stambolic V., Woodgett J.R.;
RT   "Mitogen inactivation of glycogen synthase kinase-3 beta in intact
RT   cells via serine 9 phosphorylation.";
RL   Biochem. J. 303:701-704(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Eye, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE OF 185-202.
RX   MEDLINE=99455114; PubMed=10523816; DOI=10.1038/sj.mp.4000538;
RA   Rhoads A.R., Karkera J.D., Detera-Wadleigh S.D.;
RT   "Radiation hybrid mapping of genes in the lithium-sensitive wnt
RT   signaling pathway.";
RL   Mol. Psychiatry 4:437-442(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-28.
RX   MEDLINE=99417672; PubMed=10486203; DOI=10.1006/geno.1999.5875;
RA   Lau K.F., Miller C.C.J., Anderton B.H., Shaw P.C.;
RT   "Molecular cloning and characterization of the human glycogen synthase
RT   kinase-3beta promoter.";
RL   Genomics 60:121-128(1999).
RN   [5]
RP   INTERACTION WITH DNM1L.
RC   TISSUE=Liver;
RX   MEDLINE=98401153; PubMed=9731200; DOI=10.1006/bbrc.1998.9253;
RA   Hong Y.-R., Chen C.-H., Cheng D.-S., Howng S.-L., Chow C.-C.;
RT   "Human dynamin-like protein interacts with the glycogen synthase
RT   kinase 3beta.";
RL   Biochem. Biophys. Res. Commun. 249:697-703(1998).
RN   [6]
RP   INTERACTION WITH MUC1, AND FUNCTION.
RX   PubMed=9819408;
RA   Li Y., Bharti A., Chen D., Gong J., Kufe D.;
RT   "Interaction of glycogen synthase kinase 3beta with the DF3/MUC1
RT   carcinoma-associated antigen and beta-catenin.";
RL   Mol. Cell. Biol. 18:7216-7224(1998).
RN   [7]
RP   CHARACTERIZATION.
RX   MEDLINE=98409636; PubMed=9736715; DOI=10.1073/pnas.95.19.11211;
RA   Delcommenne M., Tan C., Gray V., Rue L., Woodgett J.R., Dedhar S.;
RT   "Phosphoinositide-3-OH kinase-dependent regulation of glycogen
RT   synthase kinase 3 and protein kinase B/AKT by the integrin-linked
RT   kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:11211-11216(1998).
RN   [8]
RP   INTERACTION WITH GSK3B AND PPP2CA, PHOSPHORYLATION, AND
RP   DEPHOSPHORYLATION.
RX   MEDLINE=99121080; PubMed=9920888; DOI=10.1074/jbc.274.6.3439;
RA   Hsu W., Zeng L., Costantini F.;
RT   "Identification of a domain of Axin that binds to the serine/threonine
RT   protein phosphatase 2A and a self-binding domain.";
RL   J. Biol. Chem. 274:3439-3445(1999).
RN   [9]
RP   INTERACTION WITH NIN.
RX   MEDLINE=20461863; PubMed=11004522; DOI=10.1016/S0167-4781(00)00127-5;
RA   Hong Y.-R., Chen C.-H., Chang J.-H., Wang S.-K., Sy W.-D., Chou C.-K.,
RA   Howng S.-L.;
RT   "Cloning and characterization of a novel human ninein protein that
RT   interacts with the glycogen synthase kinase 3beta.";
RL   Biochim. Biophys. Acta 1492:513-516(2000).
RN   [10]
RP   FUNCTION, INTERACTION WITH SNAI1, AND SUBCELLULAR LOCATION.
RX   PubMed=15448698; DOI=10.1038/ncb1173;
RA   Zhou B.P., Deng J., Xia W., Xu J., Li Y.M., Gunduz M., Hung M.C.;
RT   "Dual regulation of Snail by GSK-3beta-mediated phosphorylation in
RT   control of epithelial-mesenchymal transition.";
RL   Nat. Cell Biol. 6:931-940(2004).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-390, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=15302935; DOI=10.1073/pnas.0404720101;
RA   Beausoleil S.A., Jedrychowski M., Schwartz D., Elias J.E., Villen J.,
RA   Li J., Cohn M.A., Cantley L.C., Gygi S.P.;
RT   "Large-scale characterization of HeLa cell nuclear phosphoproteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004).
RN   [12]
RP   INTERACTION WITH CABYR.
RX   PubMed=15752768; DOI=10.1016/j.bbrc.2005.02.089;
RA   Hsu H.-C., Lee Y.-L., Cheng T.-S., Howng S.-L., Chang L.-K., Lu P.-J.,
RA   Hong Y.-R.;
RT   "Characterization of two non-testis-specific CABYR variants that bind
RT   to GSK3beta with a proline-rich extensin-like domain.";
RL   Biochem. Biophys. Res. Commun. 329:1108-1117(2005).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-216, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=15951569; DOI=10.1074/mcp.M500089-MCP200;
RA   Zhang Y., Wolf-Yadlin A., Ross P.L., Pappin D.J., Rush J.,
RA   Lauffenburger D.A., White F.M.;
RT   "Time-resolved mass spectrometry of tyrosine phosphorylation sites in
RT   the epidermal growth factor receptor signaling network reveals dynamic
RT   modules.";
RL   Mol. Cell. Proteomics 4:1240-1250(2005).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-216, AND MASS
RP   SPECTROMETRY.
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-216, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-216, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [17]
RP   INTERACTION WITH PRUNE.
RX   PubMed=16428445; DOI=10.1128/MCB.26.3.898-911.2006;
RA   Kobayashi T., Hino S., Oue N., Asahara T., Zollo M., Yasui W.,
RA   Kikuchi A.;
RT   "Glycogen synthase kinase 3 and h-prune regulate cell migration by
RT   modulating focal adhesions.";
RL   Mol. Cell. Biol. 26:898-911(2006).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-216, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [19]
RP   INTERACTION WITH AXIN1.
RX   PubMed=17318175; DOI=10.1038/sj.emboj.7601607;
RA   Luo W., Peterson A., Garcia B.A., Coombs G., Kofahl B., Heinrich R.,
RA   Shabanowitz J., Hunt D.F., Yost H.J., Virshup D.M.;
RT   "Protein phosphatase 1 regulates assembly and function of the beta-
RT   catenin degradation complex.";
RL   EMBO J. 26:1511-1521(2007).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-9; TYR-216 AND THR-390,
RP   AND MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=17192257; DOI=10.1074/mcp.T600062-MCP200;
RA   Wissing J., Jaensch L., Nimtz M., Dieterich G., Hornberger R.,
RA   Keri G., Wehland J., Daub H.;
RT   "Proteomics analysis of protein kinases by target class-selective
RT   prefractionation and tandem mass spectrometry.";
RL   Mol. Cell. Proteomics 6:537-547(2007).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-216, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=17389395; DOI=10.1073/pnas.0608638104;
RA   Wolf-Yadlin A., Hautaniemi S., Lauffenburger D.A., White F.M.;
RT   "Multiple reaction monitoring for robust quantitative proteomic
RT   analysis of cellular signaling networks.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:5860-5865(2007).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-216, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-9; TYR-216; SER-219;
RP   THR-275; THR-277; THR-390 AND THR-392, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-216 AND THR-390, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-389, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [27]
RP   INTERACTION WITH MMP2.
RX   PubMed=19493954; DOI=10.1093/cvr/cvp175;
RA   Kandasamy A.D., Schulz R.;
RT   "Glycogen synthase kinase-3beta is activated by matrix
RT   metalloproteinase-2 mediated proteolysis in cardiomyoblasts.";
RL   Cardiovasc. Res. 83:698-706(2009).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-216, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=19534553; DOI=10.1021/pr900044c;
RA   Heibeck T.H., Ding S.-J., Opresko L.K., Zhao R., Schepmoes A.A.,
RA   Yang F., Tolmachev A.V., Monroe M.E., Camp D.G. II, Smith R.D.,
RA   Wiley H.S., Qian W.-J.;
RT   "An extensive survey of tyrosine phosphorylation revealing new sites
RT   in human mammary epithelial cells.";
RL   J. Proteome Res. 8:3852-3861(2009).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-7; SER-9; SER-25;
RP   SER-215; TYR-216; SER-219; THR-275; THR-277; SER-389; THR-390;
RP   THR-392; SER-398; SER-413; SER-415; SER-417 AND SER-419, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 35-386.
RX   MEDLINE=21334149; PubMed=11440715; DOI=10.1016/S0092-8674(01)00374-9;
RA   Dajani R., Fraser E., Roe S.M., Young N., Good V., Dale T.C.,
RA   Pearl L.H.;
RT   "Crystal structure of glycogen synthase kinase 3 beta: structural
RT   basis for phosphate-primed substrate specificity and autoinhibition.";
RL   Cell 105:721-732(2001).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 27-393 OF PHOSPHORYLATED
RP   GSK3B.
RX   MEDLINE=21605727; PubMed=11738041; DOI=10.1016/S0969-2126(01)00679-7;
RA   Bax B., Carter P.S., Lewis C., Guy A.R., Bridges A., Tanner R.,
RA   Pettman G., Mannix C., Culbert A.A., Brown M.J.B., Smith D.G.,
RA   Reith A.D.;
RT   "The structure of phosphorylated GSK-3beta complexed with a peptide,
RT   FRATtide, that inhibits beta-catenin phosphorylation.";
RL   Structure 9:1143-1152(2001).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 35-384 IN COMPLEX WITH AXIN1,
RP   INTERACTION WITH AXIN1 AND FRAT1, FUNCTION, ENZYME REGULATION, AND
RP   PHOSPHORYLATION AT TYR-216.
RX   PubMed=12554650; DOI=10.1093/emboj/cdg068;
RA   Dajani R., Fraser E., Roe S.M., Yeo M., Good V.M., Thompson V.,
RA   Dale T.C., Pearl L.H.;
RT   "Structural basis for recruitment of glycogen synthase kinase 3beta to
RT   the axin-APC scaffold complex.";
RL   EMBO J. 22:494-501(2003).
CC   -!- FUNCTION: Participates in the Wnt signaling pathway. Implicated in
CC       the hormonal control of several regulatory proteins including
CC       glycogen synthase, MYB and the transcription factor JUN.
CC       Phosphorylates JUN at sites proximal to its DNA-binding domain,
CC       thereby reducing its affinity for DNA. Phosphorylates MUC1 in
CC       breast cancer cells, and decreases the interaction of MUC1 with
CC       CTNNB1/beta-catenin. Phosphorylates CTNNB1/beta-catenin.
CC       Phosphorylates SNAI1.
CC   -!- CATALYTIC ACTIVITY: ATP + [tau protein] = ADP + [tau protein]
CC       phosphate.
CC   -!- ENZYME REGULATION: Activated by phosphorylation at Tyr-216.
CC       Inhibited when phosphorylated by AKT1.
CC   -!- SUBUNIT: Monomer (By similarity). Interacts with ARRB2 and DISC1
CC       (By similarity). Interacts with CABYR, MMP2, MUC1, NIN and PRUNE
CC       Interacts with AXIN1; the interaction mediates hyperphosphorylates
CC       of CTNNB1 leading to its ubiquitination and destruction. Interacts
CC       with and phosphorylates SNAI1. Interacts with DNM1L (via a C-
CC       terminal domain).
CC   -!- INTERACTION:
CC       P53396:ACLY; NbExp=1; IntAct=EBI-373586, EBI-1042794;
CC       P31749:AKT1; NbExp=1; IntAct=EBI-373586, EBI-296087;
CC       P31751:AKT2; NbExp=1; IntAct=EBI-373586, EBI-296058;
CC       O15169:AXIN1; NbExp=1; IntAct=EBI-373586, EBI-710484;
CC       Q8N0Z3:CCDC52; NbExp=1; IntAct=EBI-373586, EBI-2361917;
CC       P35222:CTNNB1; NbExp=1; IntAct=EBI-373586, EBI-491549;
CC       Q9UHI6:DDX20; NbExp=1; IntAct=EBI-373586, EBI-347658;
CC       O75398:DEAF1; NbExp=2; IntAct=EBI-373586, EBI-718185;
CC       Q9H2U1:DHX36; NbExp=1; IntAct=EBI-373586, EBI-1047643;
CC       Q811T9:Disc1 (xeno); NbExp=3; IntAct=EBI-373586, EBI-2298259;
CC       Q01844:EWSR1; NbExp=1; IntAct=EBI-373586, EBI-739737;
CC       P57678:GEMIN4; NbExp=1; IntAct=EBI-373586, EBI-356700;
CC       Q9P0R6:GSKIP; NbExp=1; IntAct=EBI-373586, EBI-1052580;
CC       P13807:GYS1; NbExp=1; IntAct=EBI-373586, EBI-963094;
CC       Q9NZI8:IGF2BP1; NbExp=1; IntAct=EBI-373586, EBI-1053892;
CC       P63085:Mapk1 (xeno); NbExp=1; IntAct=EBI-373586, EBI-397697;
CC       Q8N4C6:NIN; NbExp=1; IntAct=EBI-373586, EBI-1164022;
CC       Q9H7B2:RPF2; NbExp=1; IntAct=EBI-373586, EBI-1051960;
CC       O75533:SF3B1; NbExp=1; IntAct=EBI-373586, EBI-876542;
CC       Q16637:SMN1; NbExp=1; IntAct=EBI-373586, EBI-395421;
CC       Q9NRG4:SMYD2; NbExp=1; IntAct=EBI-373586, EBI-1055671;
CC       O95863:SNAI1; NbExp=3; IntAct=EBI-373586, EBI-1045459;
CC       P08621:SNRNP70; NbExp=1; IntAct=EBI-373586, EBI-1049228;
CC       Q9Y3F4:STRAP; NbExp=1; IntAct=EBI-373586, EBI-727414;
CC       Q14134:TRIM29; NbExp=2; IntAct=EBI-373586, EBI-702370;
CC       P49816:Tsc2 (xeno); NbExp=1; IntAct=EBI-373586, EBI-1104140;
CC       Q9H1J1:UPF3A; NbExp=1; IntAct=EBI-373586, EBI-521530;
CC       Q9NP79:VTA1; NbExp=1; IntAct=EBI-373586, EBI-740160;
CC       Q96QU8:XPO6; NbExp=1; IntAct=EBI-373586, EBI-1022896;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P49841-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P49841-2; Sequence=VSP_004790;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Expressed in testis, thymus, prostate and
CC       ovary and weakly expressed in lung, brain and kidney.
CC   -!- PTM: Phosphorylated by AKT1 and ILK1. Activated by phosphorylation
CC       at Tyr-216.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC
CC       Ser/Thr protein kinase family. GSK-3 subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L33801; AAA66475.1; -; mRNA.
DR   EMBL; BC000251; AAH00251.1; -; mRNA.
DR   EMBL; BC012760; AAH12760.1; -; mRNA.
DR   EMBL; AF098789; AAC69340.1; -; Genomic_DNA.
DR   EMBL; AF074333; AAD48517.1; -; Genomic_DNA.
DR   IPI; IPI00028570; -.
DR   IPI; IPI00216190; -.
DR   PIR; S53324; S53324.
DR   RefSeq; NP_001139628.1; -.
DR   RefSeq; NP_002084.2; -.
DR   UniGene; Hs.445733; -.
DR   PDB; 1GNG; X-ray; 2.60 A; A/B=27-393.
DR   PDB; 1H8F; X-ray; 2.80 A; A/B=35-386.
DR   PDB; 1I09; X-ray; 2.70 A; A/B=1-420.
DR   PDB; 1J1B; X-ray; 1.80 A; A/B=1-420.
DR   PDB; 1J1C; X-ray; 2.10 A; A/B=1-420.
DR   PDB; 1O9U; X-ray; 2.40 A; A=35-384.
DR   PDB; 1PYX; X-ray; 2.40 A; A/B=1-420.
DR   PDB; 1Q3D; X-ray; 2.20 A; A/B=2-420.
DR   PDB; 1Q3W; X-ray; 2.30 A; A/B=2-420.
DR   PDB; 1Q41; X-ray; 2.10 A; A/B=2-420.
DR   PDB; 1Q4L; X-ray; 2.77 A; A/B=2-420.
DR   PDB; 1Q5K; X-ray; 1.94 A; A/B=7-420.
DR   PDB; 1R0E; X-ray; 2.25 A; A/B=35-420.
DR   PDB; 1UV5; X-ray; 2.80 A; A=35-384.
DR   PDB; 2JDO; X-ray; 1.80 A; C=3-12.
DR   PDB; 2JDR; X-ray; 2.30 A; C=3-12.
DR   PDB; 2JLD; X-ray; 2.35 A; A/B=1-420.
DR   PDB; 2O5K; X-ray; 3.20 A; A=29-393.
DR   PDB; 2OW3; X-ray; 2.80 A; A/B=35-386.
DR   PDB; 2UW9; X-ray; 2.10 A; C=3-12.
DR   PDB; 2X39; X-ray; 1.93 A; C=3-12.
DR   PDB; 2XH5; X-ray; 2.72 A; C=3-12.
DR   PDB; 3CQU; X-ray; 2.20 A; C=3-12.
DR   PDB; 3CQW; X-ray; 2.00 A; C=3-12.
DR   PDB; 3DU8; X-ray; 2.20 A; A/B=1-420.
DR   PDB; 3E87; X-ray; 2.30 A; C/D=3-12.
DR   PDB; 3E88; X-ray; 2.50 A; C/D=3-12.
DR   PDB; 3E8D; X-ray; 2.70 A; C/D=3-12.
DR   PDB; 3F7Z; X-ray; 2.40 A; A/B=35-383.
DR   PDB; 3F88; X-ray; 2.60 A; A/B=35-383.
DR   PDB; 3GB2; X-ray; 2.40 A; A=34-383.
DR   PDB; 3I4B; X-ray; 2.30 A; A/B=7-420.
DR   PDB; 3L1S; X-ray; 2.90 A; A/B=7-420.
DR   PDBsum; 1GNG; -.
DR   PDBsum; 1H8F; -.
DR   PDBsum; 1I09; -.
DR   PDBsum; 1J1B; -.
DR   PDBsum; 1J1C; -.
DR   PDBsum; 1O9U; -.
DR   PDBsum; 1PYX; -.
DR   PDBsum; 1Q3D; -.
DR   PDBsum; 1Q3W; -.
DR   PDBsum; 1Q41; -.
DR   PDBsum; 1Q4L; -.
DR   PDBsum; 1Q5K; -.
DR   PDBsum; 1R0E; -.
DR   PDBsum; 1UV5; -.
DR   PDBsum; 2JDO; -.
DR   PDBsum; 2JDR; -.
DR   PDBsum; 2JLD; -.
DR   PDBsum; 2O5K; -.
DR   PDBsum; 2OW3; -.
DR   PDBsum; 2UW9; -.
DR   PDBsum; 2X39; -.
DR   PDBsum; 2XH5; -.
DR   PDBsum; 3CQU; -.
DR   PDBsum; 3CQW; -.
DR   PDBsum; 3DU8; -.
DR   PDBsum; 3E87; -.
DR   PDBsum; 3E88; -.
DR   PDBsum; 3E8D; -.
DR   PDBsum; 3F7Z; -.
DR   PDBsum; 3F88; -.
DR   PDBsum; 3GB2; -.
DR   PDBsum; 3I4B; -.
DR   PDBsum; 3L1S; -.
DR   ProteinModelPortal; P49841; -.
DR   DisProt; DP00385; -.
DR   DIP; DIP-878N; -.
DR   IntAct; P49841; 92.
DR   MINT; MINT-105006; -.
DR   STRING; P49841; -.
DR   PhosphoSite; P49841; -.
DR   PRIDE; P49841; -.
DR   Ensembl; ENST00000264235; ENSP00000264235; ENSG00000082701.
DR   GeneID; 2932; -.
DR   KEGG; hsa:2932; -.
DR   UCSC; uc003edn.1; human.
DR   UCSC; uc003edo.1; human.
DR   CTD; 2932; -.
DR   GeneCards; GC03M119540; -.
DR   HGNC; HGNC:4617; GSK3B.
DR   HPA; CAB016263; -.
DR   HPA; HPA028017; -.
DR   MIM; 605004; gene.
DR   PharmGKB; PA29009; -.
DR   eggNOG; prNOG10848; -.
DR   HOVERGEN; HBG014652; -.
DR   OMA; PSLFNFT; -.
DR   PhylomeDB; P49841; -.
DR   BRENDA; 2.7.11.26; 247.
DR   Pathway_Interaction_DB; aurora_a_pathway; Aurora A signaling.
DR   Pathway_Interaction_DB; bmppathway; BMP receptor signaling.
DR   Pathway_Interaction_DB; wnt_canonical_pathway; Canonical Wnt signaling pathway.
DR   Pathway_Interaction_DB; pi3kciaktpathway; Class I PI3K signaling events mediated by Akt.
DR   Pathway_Interaction_DB; hedgehog_glipathway; Hedgehog signaling events mediated by Gli proteins.
DR   Pathway_Interaction_DB; insulin_glucose_pathway; Insulin-mediated glucose transport.
DR   Pathway_Interaction_DB; lysophospholipid_pathway; LPA receptor mediated events.
DR   Pathway_Interaction_DB; ps1pathway; Presenilin action in Notch and Wnt signaling.
DR   Pathway_Interaction_DB; reelinpathway; Reelin signaling pathway.
DR   Pathway_Interaction_DB; ar_tf_pathway; Regulation of Androgen receptor activity.
DR   Pathway_Interaction_DB; nfat_3pathway; Role of Calcineurin-dependent NFAT signaling in lymphocytes.
DR   Pathway_Interaction_DB; kitpathway; Signaling events mediated by Stem cell factor receptor (c-Kit).
DR   Pathway_Interaction_DB; pi3kplctrkpathway; Trk receptor signaling mediated by PI3K and PLC-gamma.
DR   Reactome; REACT_11045; Signaling by Wnt.
DR   Reactome; REACT_11061; Signalling by NGF.
DR   Reactome; REACT_18266; Axon guidance.
DR   DrugBank; DB01356; Lithium.
DR   NextBio; 11619; -.
DR   ArrayExpress; P49841; -.
DR   Bgee; P49841; -.
DR   CleanEx; HS_GSK3B; -.
DR   Genevestigator; P49841; -.
DR   GermOnline; ENSG00000082701; Homo sapiens.
DR   GO; GO:0034747; C:Axin-APC-beta-catenin-GSK3B complex; IDA:BHF-UCL.
DR   GO; GO:0030877; C:beta-catenin destruction complex; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; EXP:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008013; F:beta-catenin binding; IPI:BHF-UCL.
DR   GO; GO:0051059; F:NF-kappaB binding; IPI:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IDA:MGI.
DR   GO; GO:0034236; F:protein kinase A catalytic subunit binding; IPI:BHF-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0050321; F:tau-protein kinase activity; IEA:EC.
DR   GO; GO:0060070; P:canonical Wnt receptor signaling pathway; IC:UniProtKB.
DR   GO; GO:0006983; P:ER overload response; IDA:MGI.
DR   GO; GO:0005977; P:glycogen metabolic process; IDA:BHF-UCL.
DR   GO; GO:0021766; P:hippocampus development; IMP:BHF-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptosis; IDA:MGI.
DR   GO; GO:0032091; P:negative regulation of protein binding; IDA:BHF-UCL.
DR   GO; GO:0031333; P:negative regulation of protein complex asse...; IMP:BHF-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0001954; P:positive regulation of cell-matrix adhesion; IMP:BHF-UCL.
DR   GO; GO:0045732; P:positive regulation of protein catabolic pr...; IC:BHF-UCL.
DR   GO; GO:0031334; P:positive regulation of protein complex asse...; IDA:BHF-UCL.
DR   GO; GO:0046827; P:positive regulation of protein export from ...; IDA:MGI.
DR   GO; GO:0032855; P:positive regulation of Rac GTPase activity; IMP:BHF-UCL.
DR   GO; GO:0071109; P:superior temporal gyrus development; IMP:BHF-UCL.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR002290; Ser/Thr_prot_kinase_dom.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Cytoplasm; Kinase; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Serine/threonine-protein kinase; Transferase; Wnt signaling pathway.
FT   CHAIN         1    420       Glycogen synthase kinase-3 beta.
FT                                /FTId=PRO_0000085980.
FT   DOMAIN       56    340       Protein kinase.
FT   NP_BIND      62     70       ATP (By similarity).
FT   ACT_SITE    181    181       Proton acceptor.
FT   BINDING      85     85       ATP (By similarity).
FT   MOD_RES       7      7       Phosphothreonine.
FT   MOD_RES       9      9       Phosphoserine; by PKB/AKT1.
FT   MOD_RES      25     25       Phosphoserine.
FT   MOD_RES     215    215       Phosphoserine.
FT   MOD_RES     216    216       Phosphotyrosine.
FT   MOD_RES     219    219       Phosphoserine.
FT   MOD_RES     275    275       Phosphothreonine.
FT   MOD_RES     277    277       Phosphothreonine.
FT   MOD_RES     389    389       Phosphoserine.
FT   MOD_RES     390    390       Phosphothreonine.
FT   MOD_RES     392    392       Phosphothreonine.
FT   MOD_RES     395    395       Phosphothreonine (By similarity).
FT   MOD_RES     398    398       Phosphoserine.
FT   MOD_RES     413    413       Phosphoserine.
FT   MOD_RES     415    415       Phosphoserine.
FT   MOD_RES     417    417       Phosphoserine.
FT   MOD_RES     419    419       Phosphoserine.
FT   VAR_SEQ     303    303       K -> KDSSGTGHFTSGVR (in isoform 2).
FT                                /FTId=VSP_004790.
FT   MUTAGEN       9      9       S->A: Loss of phosphorylation; No
FT                                inhibition of activity.
FT   CONFLICT     28     28       V -> G (in Ref. 4; AAD48517).
FT   CONFLICT    350    350       L -> H (in Ref. 1; AAA66475).
FT   STRAND       26     30
FT   STRAND       38     48
FT   STRAND       52     64
FT   STRAND       66     75
FT   TURN         76     78
FT   STRAND       81     88
FT   HELIX        96    102
FT   STRAND      112    120
FT   TURN        121    124
FT   STRAND      125    133
FT   HELIX       139    148
FT   HELIX       155    173
FT   TURN        174    176
FT   HELIX       184    186
FT   STRAND      187    190
FT   TURN        191    194
FT   STRAND      195    198
FT   HELIX       225    228
FT   HELIX       237    252
FT   HELIX       262    273
FT   HELIX       278    284
FT   HELIX       301    304
FT   HELIX       311    320
FT   HELIX       325    327
FT   HELIX       331    335
FT   HELIX       338    344
FT   HELIX       364    367
FT   HELIX       371    373
FT   HELIX       374    377
FT   TURN        380    383
SQ   SEQUENCE   420 AA;  46744 MW;  4ACC24D00CDBB9C3 CRC64;
     MSGRPRTTSF AESCKPVQQP SAFGSMKVSR DKDGSKVTTV VATPGQGPDR PQEVSYTDTK
     VIGNGSFGVV YQAKLCDSGE LVAIKKVLQD KRFKNRELQI MRKLDHCNIV RLRYFFYSSG
     EKKDEVYLNL VLDYVPETVY RVARHYSRAK QTLPVIYVKL YMYQLFRSLA YIHSFGICHR
     DIKPQNLLLD PDTAVLKLCD FGSAKQLVRG EPNVSYICSR YYRAPELIFG ATDYTSSIDV
     WSAGCVLAEL LLGQPIFPGD SGVDQLVEII KVLGTPTREQ IREMNPNYTE FKFPQIKAHP
     WTKVFRPRTP PEAIALCSRL LEYTPTARLT PLEACAHSFF DELRDPNVKL PNGRDTPALF
     NFTTQELSSN PPLATILIPP HARIQAAAST PTNATAASDA NTGDRGQTNN AASASASNST
//
